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ABSTRACT 23 
Alterations of epidermal growth factor receptor (EGFR) expression frequently occur 24 
in the early-stage lung adenocarcinoma. Ubiquitin-specific protease 8 (USP8) has 25 
been reported to stabilize EGFR protein at the plasma membrane through recycling 26 
pathway. Here, we examined the correlation between USP8 expression and the 27 
expression or mutation status of EGFR as well as the clinicopathological features of 28 
lung adenocarcinoma and patient outcome. Expression of EGFR and USP8 in 29 
surgically resected specimens of lung adenocarcinoma (82 cases) was examined by 30 
immunohistochemistry. Overexpression of EGFR was mutually correlated with that 31 
of USP8, and was also associated with clinicopathological features including 32 
pathological subtype, lymphatic permeation, and vascular invasion. Moreover, 33 
patients who had USP8-positive tumors had a significantly poorer outcome than those 34 
who were USP8-negative, not only overall but also patients who were EGFR-negative. 35 
Although EGFR was expressed in invasive adenocarcinoma but not in 36 
adenocarcinoma in situ (AIS), USP8 was overexpressed in not only invasive 37 
adenocarcinoma but also 38.1% of AIS cases. In vitro, USP8 regulated the expression 38 
and half-life of EGFR in immortalized AIS cells, and also cell proliferation. Our 39 
findings indicate that overexpression of USP8 in lung adenocarcinoma is an early 40 
event during the course of tumor progression, and is related to EGFR expression.  41 
 42 
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INTRODUCTION 43 
Mortality due to lung cancer has been increasing rapidly worldwide.
1
 Non-44 
small cell lung cancer (NSCLC) accounts for about 80-85% of all lung cancers, the 45 
most common histological subtype being adenocarcinoma. The Noguchi classification 46 
of small lung adenocarcinomas (2 cm in diameter or less) is correlated with the 47 
postoperative 5-year survival rate.
2
 Types A and B in the Noguchi classification 48 
(adenocarcinoma in situ, AIS) have an extremely favorable outcome with a 5-year 49 
survival rate of 100%, and show stepwise progression to type C (early but invasive 50 
adenocarcinoma), which has a relatively poorer outcome.
2, 3
 At the advanced stage, 51 
lung adenocarcinoma harbors multiple genetic abnormalities,
4, 5
 but interestingly, the 52 
mutation, amplification, and protein overexpression of epidermal growth factor 53 
receptor (EGFR) are often observed from the early stage. For complete cure, 54 
diagnosis and initiation of treatment at an early stage are essential. In this context, 55 
targeting of EGFR abnormality is thought to be a promising therapeutic strategy for 56 
lung adenocarcinoma. 57 
Somatic mutation of EGFR is the most common driver mutation, and is 58 
particularly common in NSCLC patients. The most prominent mutations in EGFR 59 
occur in exons 18-21 of the tyrosine kinase domain, and patients harboring such 60 
mutations are responsive to treatment with tyrosine kinase inhibitors (TKIs) such as 61 
gifitinib and erlotinib.
6
 Although initially these treatments elicit a rapid antitumor 62 
effect, patients develop resistance to TKIs after a median of 10-16 months of drug 63 
administration.
7, 8
 Approximately 72-90% of non-Asian NSCLC patients who undergo 64 
mutation analysis have no detectable EGFR mutation, and show a lower response to 65 
TKIs. Recent studies have shown that as well as EGFR mutation status, a high copy 66 
number or expression of wild-type EGFR is also associated with tumor progression 67 
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and patient survival.
9, 10
 However, no prognostic marker gene has yet emerged for 68 
lung adenocarcinoma patients with wild-type EGFR or low EGFR expression.  69 
In addition to a high EGFR gene copy number and mutation, ligand-dependent 70 
activation as well as recycling back to the plasma membrane via the endocytosis-71 
related pathway has been reported to play an important role in the early stage of lung 72 
cancer.
11
 Ubiquitin-specific protease 8 (USP8) is known to stabilize EGFR protein at 73 
the plasma membrane through cleavage of poly-ubiquitin from EGFR, a process 74 
known as deubiquitination, which is reversible by ubiquitination and can lead to 75 
lysosomal degradation.  76 
USP8 belongs to a ubiquitin-specific family of deubiquitination proteases 77 
(DUB) and is involved in endocytosis at endosomes.
12
 USP8 has an important 78 
physiological function in cell growth,
13
 and deletion of USP8 causes embryonic 79 
lethality in mice,
14
 similarly to deletion of EGFR.
15
 However, the relationship of 80 
USP8 to the expression or mutation status of EGFR in lung adenocarcinoma is still 81 
poorly understood.  82 
Here, we demonstrated that USP8 is correlated with the expression or 83 
mutation status of EGFR, as well as with the clinicopathological features of lung 84 
adenocarcinoma. USP8 showed overexpression in the early stage of lung 85 
adenocarcinoma and was significantly associated with shorter disease-free survival in 86 
patients overall, and also in those who were negative for EGFR expression. These 87 
findings suggest that USP8 might be a novel diagnostic and therapeutic target in 88 
early-stage lung adenocarcinoma. 89 
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METHODS AND MATERIALS 90 
Sample collection 91 
Specimens of lung adenocarcinomas that had been surgically resected at the 92 
University of Tsukuba Hospital (Ibaraki, Japan) between 1999 and 2014 were used 93 
for immunohistochemistry (IHC). We randomly collected 82 cases in which EGFR 94 
mutation had already been analyzed in order to validate chemotherapeutic options 95 
(LSI Medience Corporation. Tokyo, Japan). Follow-up information for all of the 96 
corresponding patients was obtainable from the medical records, and all of the 97 
patients provided informed consent for use of their materials. The study was 98 
approved by the Institutional Ethics Review Committee and the lung 99 
adenocarcinoma cases were classified according to the UICC TNM classification of 100 
malignant tumors (seventh edition) and the World Health Organization (WHO) 101 
classification of malignant tumors (fourth edition).
16, 17
 102 
 103 
Immunohistochemistry (IHC) 104 
 Sections 4 µm thick were cut from formalin-fixed paraffin-embedded (FFPE) 105 
tissue blocks. The sections were deparaffinized and rehydrated, followed by blocking 106 
of endogenous peroxidase using 3% H2O2 for 30 min. Subsequently, antigen retrieval 107 
was performed using an autoclave with 10 mM Tris-EDTA buffer (pH 9.0) at 105°C 108 
for 10 min. Immunostaining was performed using a Dako Autostainer Link 48 109 
(Agilent Technologies, Santa Clara, CA) with the appropriate primary antibody and 110 
REAL Envision HRP rabbit/mouse (Agilent Technologies) as a secondary antibody. 111 
The immunoreactivity was detected with DAB (Dako REAL Envision Detection 112 
System; Agilent Technologies), and counterstaining was performed with hematoxylin 113 
for 1 min. Evaluation of USP8 and EGFR expression was based on the intensity of 114 
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cytoplasmic staining. The staining was judged to be positive when the cytoplasm of 115 
the tumor cells was stained more strongly than that of the alveolar epithelium. Rabbit 116 
polyclonal anti-USP8 antibody (Bethyl Laboratories, Montgomery, TX) and mouse 117 
monoclonal anti-EGFR antibody (Agilent Technologies, Clone DAK-H1-WT) were 118 
used as the primary antibodies. The evaluation of immunoreactivity was used two-tier 119 
grading as negative with non-stained and positive with diffusely positive. 120 
 121 
Cell culture and conditions 122 
The PL16T cell line was established in our laboratory from a surgically 123 
resected AIS of the lung.
18
 PL16T was maintained in MCDB153HAA (Wako, Osaka, 124 
Japan) supplemented with 2% FBS (Sigma-Aldrich, St. Louis, MO), 0.5 ng/ml human 125 
EGF (Toyobo, Tokyo, Japan), 5 µg/ml human insulin (Wako), 72 ng/ml 126 
hydrocortisone (Wako), 40 µg/ml human transferrin (Sigma-Aldrich), and 20 ng/ml 127 
sodium selenate (Sigma-Aldrich). The cells were cultured in a 5% CO2 incubator at 128 
37°C and passaged every 3-4 days. 129 
 130 
Plasmid and siRNA transfection 131 
Flag-USP8 plasmid was purchased from Addgene (Cambridge, MA). The day 132 
before transfection, PL16T cells were plated to obtain 80% confluence on the day of 133 
transfection. Fugene HD (Promega, Madison, WI) was used for plasmid transfection. 134 
USP8-specific siRNA (forward, GGACAACCAGAAAGUGGAAUUCUAA and 135 
reverse, UUAGAAUUCCACUUUCUGGUUGUCC) from Thermo Fisher Scientific 136 
and lipofectamine RNAiMAX (Thermo Fisher Scientific), were used for siRNA 137 
transfection. The final siRNA concentration used for PL16T cells was 5 nM. 138 
Transfections were performed in accordance with the manufacturer’s protocol. The 139 
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cells were incubated at 37°C in a 5% CO2 incubator for 24 or 48 h and then further 140 
analyzed.    141 
 142 
Quantitative real-time PCR analysis  143 
To confirm the transfection efficiency of the Flag-USP8 plasmid or siUSP8, 144 
PL16T cells were evaluated using quantitative real-time RT-PCR. Total RNA was 145 
extracted from siUSP8-transfected PL16T cells using an RNeasy Mini Plus Kit 146 
(QIAGEN) and the quality was evaluated using an Agilent 2100 Bioanalyzer (Thermo 147 
Fisher Scientific). One microgram of total RNA per 20 µl of the reaction mixture was 148 
converted to cDNA using a High Capacity cDNA Reverse Transcription Kit (Thermo 149 
Fisher Scientific). Quantitative real-time PCR was performed with SYBR Premix Ex 150 
TaqTM (Perfect Real Time; Takara Bio, Shiga, Japan) on a GeneAmp 7300 Sequence 151 
Detection System (Thermo Fisher Scientific) in accordance with the manufacturer’s 152 
protocol.  153 
 154 
Western blot analysis 155 
Total protein from the cells was prepared on ice using Mammalian Protein 156 
Extraction Reagent (M-PER; Thermo Fisher Scientific) containing a Halt protease 157 
and phosphatase inhibitor cocktail (Thermo Fisher Scientific). The total protein in the 158 
lysates was measured using a BCA protein assay kit (Thermo Fisher Scientific). Total 159 
protein aliquots (20 µg) were mixed with 5x sample loading buffer supplemented with 160 
DTT, denatured at 95°C for 5 min, and electrophoresed on 10% Mini-PROTEAN 161 
TGX Precast Gels (Bio-Rad Laboratories, Hercules, CA). Proteins were transferred to 162 
polyvinylidene difluoride membranes using an iBlot gel transfer system (Thermo 163 
Fisher Scientific). The blots were then blocked and probed with various antibodies 164 
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obtained from the following commercial sources: USP8 from Cell Signaling 165 
Technology (Denvers, MA); EGFR from Medical & Biological Laboratories (Aichi, 166 
Japan); Flag and β-actin from Sigma-Aldrich. After extensive washing, 167 
immunoreactivity was detected with specific secondary antibodies conjugated to 168 
horseradish peroxidase (Thermo Fisher Scientific). Protein bands were visualized 169 
using SuperSignal West Femto Maximum sensitivity substrate (Thermo Fisher 170 
Scientific) and images were captured on a ChemiDoc
 
Touch Imaging System (Bio-171 
Rad Laboratories). 172 
 173 
Immunofluorescence  174 
PL16T cells were plated on collagen-coated cover slips (Iwaki Biosciences, 175 
Tokyo, Japan) and fixed with 10% neutral buffered formalin. They were then 176 
incubated with anti-EGFR conjugated with Alexa Fluor 488 antibody (Cell Signaling 177 
Technology) for 1 h at room temperature, and analyzed using a fluorescence 178 
microscope (Biorevo BZ-9000; Keyence, Osaka, Japan). 179 
 180 
Pulse chase assay 181 
Pulse-chase assay was performed followed by the protocol reported previously 182 
with some modification.
19
 After transfection with siUSP8 for 48 h, the cells were 183 
washed with PBS and incubated with prewarmed DMEM medium without Met/Cys 184 
for 30 min at 37°C in a 5% CO2 incubator. The cells were labeled with 
35
S-Met/Cys 185 
(10 µCi/ml) as the pulse radioisotope in DMEM medium without Met/Cys for 30 min 186 
at 37°C in a 5% CO2 incubator. For chasing of the labeled protein, the isotope-labeled 187 
cells were washed 3 times with culture medium and incubated with the culture 188 
medium for 0, 2, 5, and 10 h. After chasing, total protein was extracted from the cells 189 
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using IP Lysis Buffer (Thermo Fisher Scientific) containing a Halt protease and 190 
phosphatase inhibitor cocktail (Thermo Fisher Scientific). The labeled proteins were 191 
isolated from other cellular proteins by immunoprecipitation with EGFR antibody and 192 
subjected to Western blot analysis. For quantitative determination of the proteins, the 193 
membrane containing the metabolically labeled EGFR was subjected to β–ray 194 
scanning using a Typhoon FLA7000 (GE Healthcare, Chicago, IL) image analysis 195 
system. 196 
 197 
Proliferation assay 198 
For analysis of cellular proliferation activity, a Cell Counting Kit-8 (WST-8)  199 
(Dojindo Laboratories, Kumamoto, Japan) was used in accordance with the 200 
manufacturer’s protocol after plasmid or siRNA transfection.      201 
    202 
Statistical analysis 203 
Group results are expressed as mean ± SD. Data were compared between 204 
groups using the t test for 2-tailed distributions and the paired t test. Differences at P 205 
*<0.05, **<0.01, and ***<0.001 were considered significant. SPSS 22 statistical 206 
software (SPSS, Chicago, IL) was used for IHC data analysis as follows. Correlations 207 
of clinicopathological features with the expression and mutation status of EGFR or 208 
expression of USP8 were analyzed using the chi-squared test. Disease-free survival 209 
was examined using the Kaplan-Meier method, and the significance of differences 210 
between survival curves was evaluated using log-rank test. Univariate and 211 
multivariate analysis was conducted using the Cox proportional hazards model. 212 
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RESULTS 213 
Overexpression of EGFR and correlation with clinicopathological features 214 
We examined EGFR expression in both normal lung tissue and tumor tissue 215 
(Fig. S1a, b). EGFR expression in tumor tissue was higher than that in normal tissue, 216 
and staining was strong in the cytoplasm and on the cell membrane of tumor cells. 217 
EGFR expression was detected in 26.8% (22/82) of the cases and was significantly 218 
correlated with pathological subtype, pathological stage, lymphatic permeation, and 219 
vascular invasion (Table 1, left).   220 
 221 
EGFR mutation status and correlation with clinicopathological features 222 
Next, we investigated the mutation status of EGFR in the same cases. 223 
Similarly to previous reports, mutant EGFR containing the E746-A750 deletion in 224 
exon 19 and L858R in exon 21 was detected in 35.4% (29/82) of the cases and was 225 
significantly correlated with patient gender, the Noguchi classification, pathological 226 
subtype, pathological stage, lymphatic permeation, and vascular invasion (Table 1, 227 
right). The frequency of EGFR mutation was significantly higher in women (75.9%, 228 
22/29) than in men. Acinar adenocarcinoma was the most common dominant 229 
histological subtype with mutant EGFR (12/29; 41.4% of all mutant cases, 12/18; 230 
66.7% of cases with an acinar pattern). Moreover, EGFR mutation status was 231 
correlated with EGFR expression; mutation was detected in 63.6% (14/22) of cases 232 
that were EGFR-positive (Table S1). 233 
 234 
Overexpression of USP8 and correlation with clinicopathological features 235 
USP8 showed higher expression in tumor tissue than in normal lung tissue 236 
(Fig. S1c, d) and was stained mainly in the cytoplasm. USP8 expression was observed 237 
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in 65.9% (54/82) of the cases and was correlated with the Noguchi classification, 238 
pathological subtype, lymphatic permeation, and vascular invasion (Table 2). 239 
Overexpression of USP8 was detected in not only invasive adenocarcinoma (44/57, 240 
77.2%) but also AIS (8/21, 38.1%). 241 
 242 
Correlation between expressions of USP8 and the expression and mutation status 243 
of EGFR 244 
Next, we analyzed the correlation between expressions of USP8 and mutation 245 
status of EGFR. We found that all cases showing EGFR overexpression also had 246 
USP8 overexpression, the two being significantly correlated with each other (Table 3, 247 
upper). Fig.1 shows representative cases in which expression of EGFR was consistent 248 
with that of USP8.  Moreover, we confirmed that USP8 expression was in correlation 249 
with EGFR mutation status (Table 3, lower). Similarly to EGFR expression, USP8 250 
expression and EGFR mutation status were significantly correlated, and 86.2% (25/29) 251 
of cases with EGFR mutation showed USP8 overexpression. 252 
 253 
Analysis of EGFR and USP8 expression in relation to survival 254 
To examine the prognostic implications of EGFR mutation status and 255 
expression of EGFR or USP8, we analyzed the disease-free survival of the patients. 256 
The Kaplan-Meier curves indicated that patients with positive expression of EGFR or 257 
USP8 had a significantly poorer outcome than those lacking such expression (Fig. 2a, 258 
b). However, the mutation status of EGFR did not show any association with patient 259 
outcome (Fig. 2c). 260 
Additionally, multivariate analysis of the variables shown to be significant by 261 
univariate analysis revealed that vascular invasion, lymphatic permeation, and 262 
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pathological stage were independently associated with disease-free survival, whereas 263 
EGFR or USP8 expression was not (Table S2). 264 
Since our IHC results showed that USP8 overexpression was present even in 265 
AIS, we speculated that USP8 overexpression might be an earlier event than the 266 
appearance of EGFR abnormalities and possibly related to prognosis, even in patients 267 
who had no EGFR abnormalities including overexpression or mutation. To explore 268 
this possibility, we selected EGFR-negative or EGFR wild-type cases and analyzed 269 
patient outcome using the Kaplan-Meier curves obtained. Interestingly, in the EGFR-270 
negative or EGFR wild-type population, patients with USP8 overexpression had 271 
significantly poorer outcome than those without it (Fig. 2d, e), indicating that USP8 272 
might be a useful prognostic marker for patients with no EGFR abnormalities.  273 
 274 
Regulation of EGFR expression by USP8 in immortalized AIS cells 275 
Our IHC results had indicated that USP8 was overexpressed in lung 276 
adenocarcinoma from an early stage, such as AIS or minimally invasive 277 
adenocarcinoma (MIA). Therefore, we employed an immortalized AIS cell line, 278 
PL16T, for analysis of USP8 function in relation to EGFR expression. To examine the 279 
effects of USP8 overexpression or knockdown on EGFR expression in PL16T, we 280 
transfected the cells with Flag-USP8 or siUSP8. To confirm the transfection 281 
efficiency, we examined the mRNA and protein of USP8 (Fig. 3a, b). Overexpression 282 
of USP8 led to up-regulation of EGFR expression, whereas knockdown of USP8 led 283 
to down-regulation of total EGFR, not only on the cell surface but also in the 284 
cytoplasm (Fig. 3b, c). In addition, knockdown of USP8 shortened the half-life of 285 
EGFR relative to the control, indicating that USP8 helps to stabilize EGFR by 286 
inhibiting its degradation (Fig. 3d).  Furthermore, cellular proliferation was reduced 287 
Page 12 of 36Pathology International
For Peer Review
 13
after USP8 knockdown, and accelerated after USP8 overexpression, relative to the 288 
control (Fig. 3e). These changes in cellular proliferation are thought to result from 289 
regulation of EGFR expression by USP8. Thus, our in vitro results suggested that 290 
USP8 controls the expression of EGFR, thus possibly affecting the clinical outcome. 291 
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DISCUSSION 292 
In this study, we demonstrated that expression of EGFR and USP8 in lung 293 
adenocarcinoma was higher in tumor tissue than in normal lung tissue, and was 294 
associated with clinicopathological features such as the pathological subtype, 295 
lymphatic permeation, and vascular invasion (Tables 1, 2). Moreover, the expression 296 
and mutation status of EGFR were mutually correlated.
20
 Since EGFR mutation 297 
accelerates tumor cell proliferation and results in gene amplification, 
7, 10, 21
 EGFR 298 
abnormalities such as mutation, amplification, and overexpression might occur 299 
sequentially in tandem with the stepwise progression of lung adenocarcinoma, 300 
particularly at the early stage such as AIS. 
3, 7
 Additionally, consistent with a previous 301 
report,
22
 the frequency of EGFR mutation was found to be associated with 302 
histological phenotype. 303 
Although many researchers have investigated the association between EGFR 304 
expression and amplification, the results have not been consistent; Lee et al. and 305 
Sasaki et al. found a significant correlation between them,
10, 23
 whereas Tang et al. did 306 
not.
11
 This discrepancy suggests that not only genetic alteration but also various 307 
regulatory mechanisms occurring at the protein level might influence EGFR 308 
expression. USP8 is one of the EGFR-regulating factors that induce EGFR protein 309 
recycling through deubiquitination.
24
 In this study, we showed that the expression of 310 
USP8 was significantly associated with that of EGFR. Overexpression of USP8 311 
showed 38.1% of AIS cases (Table 2), suggesting that alteration of USP8 might be an 312 
early event similar to overexpression of EGFR. Based on these findings, we suggest 313 
that these alterations occur sequentially and are closely related to the stepwise 314 
progression of lung adenocarcinoma.  315 
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Overexpression of USP8 was detected in more than half of the cases of lung 316 
adenocarcinoma (Table 2). Chiara et al. screened alteration of DUBs in human 317 
cancers including those of the breast, colon-rectum, lung, stomach, kidney, prostate, 318 
non-Hodgkin’s lymphoma, and melanoma, and found that USP9X, USP10, USP11, 319 
USP22, and USP24, but not USP8, were overexpressed in lung cancer.
25
 The 320 
observed discrepancy of USP8 positivity might be attributable to differences in the 321 
antibody or methodology used for IHC, and the freshness of the specimens employed.  322 
Moreover, in IHC, the number of cases positive for USP8 was higher than that 323 
of cases positive for EGFR. We selected 60 cases that lacked EGFR expression and 324 
examined the association between USP8 expression and patient outcome. 325 
Interestingly, patients whose cancers were positive for USP8 had a significantly 326 
poorer outcome than those whose cancers were USP8-negative (Fig. 1, 2c), 327 
suggesting that USP8 might be a novel prognostic marker even in patients with 328 
EGFR-negative cancers. 329 
Because we collected the samples in which EGFR mutation had already 330 
been analyzed, it can be easily envisaged that they might include high number of 331 
recurrence cases. Indeed, recurrence rate of our tested sample (36/82 cases, 332 
43.9 %) was higher than overall lung adenocarcinoma cases (156/652 cases, 333 
23.9%) between 1999 and 2014 at university of Tsukuba Hospital. Therefore, in 334 
order to understand our result more correctly, we are planning additional large 335 
scale examination for expression of USP8 and EGFR as well as mutation status of 336 
EGFR. 337 
Additionally, our in vitro experiments using immortalized AIS cells revealed that 338 
USP8 regulates EGFR expression at the cell membrane and in the cytoplasm, as well 339 
as its half-life, and cellular proliferation (Fig. 3). Therefore, our results imply that 340 
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overexpression of USP8 might stabilize EGFR expression by inducing 341 
deubiquitination of EGFR from the early stage of lung adenocarcinoma such as AIS 342 
which does not show invasiveness.  343 
USP8 activity is tightly controlled by scaffold proteins such as 14-3-3 344 
proteins26 or post-translational modification such as phosphorylation27. Most of 345 
DUBs undergo phosphorylation by protein kinases that can switch their activity 346 
into on or off27. In case of USP8, its stability and phosphorylation are regulated 347 
by AKT28 and Src29, which are representative oncogenic signaling factors located 348 
in the downstream EGFR. In addition, USP19 was reported to have auto-349 
deubiquitination function, removing ubiquitin moieties from USP19 protein 350 
itself30. USP8 might also have similar function to control its own stability. Based 351 
on these facts, we expect that oncogenic signaling such as AKT and Src and the 352 
auto deubiquitination activity of USP8 may contribute overexpression of USP8 in 353 
lung adenocarcinoma. 354 
Similarly to USP8, heat shock protein 90 (HSP90) acts as a chaperone 355 
protein that is known to stabilize not only wild-type but also mutant EGFR by 356 
regulation of its degradation after chemotherapy and radiotherapy31, 32. 357 
Moreover, HSP90 inhibitor such as AUY922, potential agents for cancer 358 
treatment, effectively decreased cellular proliferation in lung adenocarcinoma 359 
cells harboring mutant EGFR by downregulation of EGFR and MET expression, 360 
which subsequently led to reduction of AKT-pathway33 likewise USP8 inhibitor 361 
effect on RTKs34.  However, recent clinical study of AUY922 in EGFR mutated 362 
patients of lung adenocarcinoma observed partial responses of this treatment 363 
but the dose and duration of the combination treatment with AUY922 and 364 
erlotinib to avoid rapid tumor development was limited by toxicities35. Similarly 365 
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to HSP90, USP8 might be also worth verifying its diagnostic or therapeutic 366 
usefulness.  367 
Unlike the current treatment strategy for advanced adenocarcinoma, no 368 
therapeutic approach for early-stage lung adenocarcinomas such as AIS has yet been 369 
established, except for surgical resection.
36
 Based on our findings, we believe that 370 
USP8 could be an attractive therapeutic target for early-stage lung adenocarcinoma. 371 
Additionally, small-molecule inhibitors targeting USP8 have been developed, and are 372 
very selective. Therefore, our finding would seem to justify the development of a 373 
USP8 inhibitor for treatment of lung adenocarcinoma. 374 
In conclusion, based on our findings, we believe that USP8 appears to be a 375 
suitable protein for use as a prognostic marker in early-stage lung adenocarcinoma, 376 
and might also be a promising therapeutic target.  377 
 378 
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 Table 1 481 
Expression of epidermal growth factor receptor (EGFR) and its mutation status in relation to 482 
clinicopathological features of patients with lung adenocarcinoma. 483 
Clinicopathological 
 features 
EGFR Expression Total  
patients 
P-
value 
EGFR mutation status Total  
patients 
P-value 
Negative Positive Wild-type Mutant 
Age (yr) 
   
0.285    0.684 
≤60 18 4 22 15 7 22  
>60 42 18 60 38 22 60  
Gender 
   
0.465    0.002 
Female 30 13 43 21 22 43 ** 
Male 30 9 39 32 7 39  
Noguchi classification 
   
0.066    <0.001 
Type A 8 0 8 8 0 8 *** 
Type B 12 1 13 13 0 13  
Type C' 2 0 2 
 
2 0 2  
Type C 4 3 7 2 5 7  
Type D 1 0 1 1 0 1  
Total 27 4 31 26 5 31  
Pathological subtype 0.021    0.001 
AIS 20 1 21 * 21 0 21 *** 
MIA 2 0 2 
 
2 0 2  
Invasive 
adenocarcinoma     
  Lepidic 10 2 12 5 7 12  
  Acinar 9 9 18 
 
6 12 18  
  Papillary 9 3 12 
 
5 7 12  
  Micropapillary 1 0 1 1 0 1  
  Solid 7 7 14 11 3 14  
IMA 2 0 2 
 
2 0 2  
Pathological stage
†
 0.001    0.001 
Stage I 37 5 42 *** 33 9 42 *** 
Stage II 11 5 16 
 
9 7 16  
Stage III 8 12 20 10 10 20  
Stage IV 4 0 4 1 3 4  
Lymphatic 
permeation       0.035       0.012 
Negative 40 9 49 * 37 12 49 * 
Positive 20 13 33 
 
16 17 33  
Vascular invasion       0.002       0.006 
Negative 39 6 45 ** 35 10 45 ** 
Positive 21 16 37 18 19 37  
 484 
†
Stage I includes IA and IB, stage II includes IIA and IIB, stage III includes IIIA and IIIB. Correlation between 485 
expression of EGFR or mutation status and clinicopathological features was analyzed using chi-squared test. 486 
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AIS, adenocarcinoma in situ); MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous 487 
adenocarcinoma. 488 
 489 
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Table 2  490 
Ubiquitin-specific protease 8 (USP8) expression in relation to clinicopathological features of 491 
patients with lung adenocarcinoma. 492 
Clinicopathological 
 features 
USP8 Expression Total  
patients 
P-value 
Negative Positive 
Age (yr) 0.434 
≤60 9 13 22 
>60 19 41 60 
 Gender 0.750 
Female 14 29 43 
 Male 14 25 39 
Noguchi classification 
   
0.018 
Type A 7 1 8 * 
Type B 6 7 13 
 Type C' 2 0 2 
Type C 1 6 7 
 Type D 0 1 1 
Total 16 15 31 
Pathological subtype 0.021 
AIS 13 8 21 * 
MIA 2 0 2 
 Invasive adenocarcinoma 
  Lepidic 3 9 12 
   Acinar 3 15 18 
  Papillary 4 8 12 
  Micropapillary 0 1 1 
   Solid 3 11 14 
IMA 0 2 2 
 Pathological stage
 †
 0.060 
Stage I 20 22 42 
 Stage II 4 12 16 
Stage III 3 17 20 
Stage IV 1 3 4 
 Lymphatic permeation       <0.001 
Negative 25 24 49 *** 
Positive 3 30 33 
Vascular invasion 
   
0.002 
Negative 22 23 45 ** 
Positive 6 31 38   
 493 
†
Stage I includes IA and IB, stage II includes IIA and IIB, stage III includes IIIA and IIIB. Correlation 494 
between expression of USP8 and clinicopathological feature was analyzed using chi-squared test. 495 
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AIS, adenocarcinoma in situ); MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous 496 
adenocarcinoma. 497 
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Table 3 498 
Correlation between expression of ubiquitin-specific protease 8 (USP8) and the expression and 499 
mutation status of epidermal growth factor receptor (EGFR).  500 
 USP8 expression Total  
patients 
P-value 
 Negative Positive 
EGFR expression    <0.001 
  Negative 28 (46.7%) 32 (53.3%) 60  *** 
  Positive 0   22 (100%) 22   
EGFR mutation status    0.004 
  Wild-type 24 (45.3%) 29 (54.7%) 53  ** 
  Mutant 4 (13.7%) 25 (86.2%) 29   
     Exon 19 (E746-A750 del) 2/4  9/25 11/29   
     Exon 21 (L858R)  2/4 16/25 18/29   
 501 
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FIGURE LEGENDS 502 
Figure 1 Immunohistochemistry of epidermal growth factor (EGFR) and 503 
ubiquitin-specific protease 8 (USP8) in lung adenocarcinoma and normal lung 504 
tissues.  505 
Normal: peripheral lung tissue. #1. AIS: adenocarcinoma in situ showing negativity 506 
for both EGFR and USP8. #2. AIS: adenocarcinoma in situ showing negativity for 507 
EGFR and positivity for USP8. #3. Lepidic: Lepidic adenocarcinoma showing 508 
negativity for both EGFR and USP8. #4. Solid: Solid adenocarcinoma showing 509 
negativity for EGFR but positivity for USP8. #5. Solid: Solid adenocarcinoma 510 
showing positivity for both EGFR and USP8.  511 
 512 
Figure 2 Correlation between patient outcome and epidermal growth factor 513 
(EGFR) expression, EGFR mutation status, or ubiquitin-specific protease 8 514 
(USP8) expression. 515 
Disease-free survival was analyzed using Kaplan-Meier curves. Patients with tumors 516 
expressing EGFR (a) and USP8 (b) showed significantly poorer outcome than those 517 
with tumors lacking such expression. EGFR mutation-positive patients (c) had a 518 
relatively poorer outcome than patients whose tumors had wild-type EGFR. USP8 519 
expression was also associated with a significantly poorer outcome in the EGFR-520 
negative population (d) and the EGFR wild-type population (e). 521 
 522 
Figure 3 Regulatory effect of ubiquitin-specific protease 8 (USP8) on epidermal 523 
growth factor (EGFR) expression in immortalized adenocarcinoma in situ (AIS) 524 
cells. 525 
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(a) 24 h after transfection with the Flag-USP8 plasmid or 48 h after transfection with 526 
siUSP8, total RNA was extracted from immortalized AIS cells (PL16T). The 527 
transfection efficiency of the Flag-USP8 plasmid or siUSP8 was assessed at the 528 
mRNA level using real-time RT PCR. Values are mean ± standard deviation. P-value 529 
<0.001 (two-sided Student t test). (b) EGFR Western blotting was carried out using 530 
PL16T cells after overexpression or knockdown of USP8. β-Actin was used as a 531 
control to verify equal loading of protein (20 µg).  (c) EGFR immunofluorescence 532 
after knockdown of USP8 showed reduction of the EGFR signal at not only the 533 
plasma membrane but also in the cytoplasm. (d) A pulse-chasing assay was carried 534 
out after knockdown of USP8 in PL16T. After siUPS8 transfection, radioisotope-535 
labeled EGFR was chased at the indicating times. The half-life of EGFR in the cells 536 
transfected with siUSP8 was shorter in comparison with siCON. (e) After 537 
overexpression or knockdown of USP8, cellular proliferation assay was carried out 538 
using PL16T.  Values are mean ± standard deviation. P-value <0.001 (two-sided 539 
Student t test). 540 
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Supplementary Figure S1 541 
Immunohistochemistry for epidermal growth factor (EGFR) or ubiquitin-specific 542 
protease 8 (USP8). a and c; peripheral normal lung tissue, b and d; tumor lung tissue. 543 
Supplementary Table S1 544 
Correlation between expression and mutation status of epidermal growth factor 545 
(EGFR).  546 
Supplementary Table S2 547 
Univariate and multivariate analysis using the Cox proportional hazards model. 548 
 549 
 550 
 551 
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Supplementary material 1 
Supplementary Table S1 2 
Correlation between expression and mutation status of EGFR.  3 
 EGFR expression Total  
patients 
P-value 
 Negative Positive 
EGFR mutation status    0.001 
  Wild-type 45 (84.9%) 8 (15.1%) 53          *** 
  Mutant 15 (51.7%) 14 (48.3%) 29   
     EX19 (E746-A750 del)    5/15  6/14 11/29   
     EX21 (L858R)  10/15  8/14 18/29   
 4 
  5 
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Supplementary Table S2 6 
Univariate and multivariate analysis using the Cox proportional hazards model. 7 
Clinicopathological 
 features 
Univariate analysis 
 
Multivariate analysis 
 
HR 95% CI 
p-
value 
  
HR 95% CI p-value 
  
Gender 
(Female vs Male) 
0.630 0.279-1.421 0.266 
     
Age (yr) 
(≤60 vs >60) 
1.235 0.817-1.868 0.317 
     
Vascular invasion 
(Negative vs Positive) 
0.285 0.164-0.494 <0.001 *** 0.446 
0.310-
0.755 
0.001 *** 
Lymphatic permeation 
(Negative vs Positive) 
0.360 0.226-0.575 <0.001 *** 0.564 
0.245-
0.811 
0.008 ** 
Pathological stage 
(I, II vs III, IV) 
0.339 0.261-0.611 <0.001 *** 0.483 
0.330-
0.967 
0.037 * 
EGFR expression 
(Negative vs Positive) 
0.550 0.361-0.839 0.005 ** 0.748 
0.470-
1.192 
0.222 
 
EGFR mutation status 
(Wild-type vs Mutant) 
1.159 0.754-1.781 0.502 
 
      
 
USP8 expression 
(Negative vs Positive) 
0.446 0.243-0.817 0.009 ** 0.923 
0.452-
1.887 
0.827  
 8 
 9 
 10 
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